Price Alert

Exicure Inc. (XCUR)

NASDAQ: XCUR · Real-Time Price · USD

6.50

-0.05 (-0.76%)

At close: Aug 19, 2025, 11:39 AM

-0.76% (1D)

Bid	6.5
Market Cap	41.07M
Revenue (ttm)	n/a
Net Income (ttm)	-5.86M
EPS (ttm)	-3.86
PE Ratio (ttm)	-1.68
Forward PE	n/a
Analyst	n/a

Ask	6.75
Volume	5,473
Avg. Volume (20D)	117,024
Open	6.56
Previous Close	6.55
Day's Range	6.50 - 6.85
52-Week Range	1.44 - 36.00
Beta	3.68

About XCUR

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol XCUR

Website n/a

Full Company Profile

Why Price Moved

2 weeks ago

-3.37%

Exicure shares are trading higher after the compan... Unlock content with Pro Subscription

6 months ago

-15.07%

Exicure shares are trading higher after the company announced it entered into a share purchase agreement to acquire all of the issued and outstanding equities of GPCR Therapeutics.

News

1 week ago · fool.com

Exicure Posts Wider Loss in Fiscal Q2

1 week ago · businesswire.com

Exicure, Inc. Reports Second Quarter 2025 Financial Results

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure, Inc. Reports Second Quarter 2025 Financial Results.

2 weeks ago · businesswire.com

Exicure, Inc. (Nasdaq: XCUR) Regains Compliance with Nasdaq Filing Requirements

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR) Regains Compliance with Nasdaq Filing Requirements.

2 weeks ago · businesswire.com

Exicure Completes the Last Patient, Last Visit in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure Completes the Last Patient, Last Visit in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients.